Volume 59, Issue 5, Pages (May 2001)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

A skeptical view of assisted home peritoneal dialysis

LDL cholesterol in CKD—to treat or not to treat?

Volume 57, Issue 5, Pages (May 2000)

Reduced hemodialysis-induced oxidative stress in end-stage renal disease patients by electrolyzed reduced water Kuo-Chin Huang, Chih-Ching Yang, Kun-Tai.

Volume 66, Issue 6, Pages (December 2004)

Volume 54, Issue 2, Pages (August 1998)

Iron status and iron supplementation in peritoneal dialysis patients

Volume 88, Issue 5, Pages (November 2015)

Volume 67, Issue 2, Pages (February 2005)

Naïve and central memory T-cell lymphopenia in end-stage renal disease

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,

Volume 57, Issue 5, Pages (May 2000)

Volume 66, Issue 1, Pages (July 2004)

Heparin-coated dialyzer membranes: is non-inferiority good enough?

John M. Arthur, M.D.Ph.D., Shazia Shamim Kidney International

C-reactive protein and dialysis access

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population Mark J. Sarnak, Bertrand L. Jaber Kidney International

Volume 63, Issue 6, Pages (June 2003)

Volume 65, Issue 4, Pages (April 2004)

Yasuhiro Hamada, Masafumi Fukagawa Kidney International

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Kamyar Kalantar-Zadeh Kidney International

Vitamin E–bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells Shuzo Kobayashi, Hidekazu.

Reduced hemodialysis-induced oxidative stress in end-stage renal disease patients by electrolyzed reduced water Kuo-Chin Huang, Chih-Ching Yang, Kun-Tai.

Volume 58, Issue 1, Pages (July 2000)

George A. Kaysen, Burl R. Don

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

C.-C. Yang, S.-P. Hsu, M.-S. Wu, S.-M. Hsu, C.-T. Chien

Proinflammatory effects of iron sucrose in chronic kidney disease

N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment Martina Franz, Wolfgang Woloszczuk, Walter.

Volume 61, Issue 2, Pages (February 2002)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 87, Issue 2, Pages (February 2015)

Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients Der-Cherng Tarng,

Volume 73, Pages S5-S17 (April 2008)

LDL cholesterol in CKD—to treat or not to treat?

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments R. Mishler, J.J. Sands, N.J. Ofsthun,

The calcium–phosphorus in guidelines for CKD-MBD

Volume 67, Pages S48-S51 (January 2005)

Volume 75, Issue 1, Pages (January 2009)

Blood pressure targets in hemodialysis patients

Volume 69, Issue 10, Pages (May 2006)

Volume 67, Issue 1, Pages (January 2005)

Volume 73, Issue 9, Pages (May 2008)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Alternate-day dialysis may be needed for hemodialysis patients

Volume 71, Issue 6, Pages (March 2007)

Pathogenesis of refractory secondary hyperparathyroidism

The initiation and progression of sickle cell nephropathy

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 79, Issue 2, Pages (January 2011)

Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis N.-Y. Zalunardo, C.-L. Rose, I.W.Y.

A skeptical view of assisted home peritoneal dialysis

Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes Sr. Anne B. Bakewell, Rob M. Higgins, Mair.

Volume 55, Issue 5, Pages (May 1999)

Volume 68, Issue 1, Pages (July 2005)

Volume 72, Issue 2, Pages (July 2007)

Volume 63, Issue 2, Pages (February 2003)

Volume 72, Issue 2, Pages (July 2007)

Volume 63, Issue 1, Pages (January 2003)

Volume 80, Issue 10, Pages (November 2011)

Charles A. Herzog Kidney International

Volume 62, Issue 5, (November 2002)

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 58, Issue 2, Pages (August 2000)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 67, Issue 5, Pages (May 2005)

Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis (HD) patients. Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis.

Presentation transcript:

Volume 59, Issue 5, Pages 1943-1950 (May 2001) Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters Minoru Satoh, Yasushi Yamasaki, Yoshio Nagake, Junko Kasahara, Masami Hashimoto, Norio Nakanishi, Hirofumi Makino Kidney International Volume 59, Issue 5, Pages 1943-1950 (May 2001) DOI: 10.1046/j.1523-1755.2001.0590051943.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Serum levels of malondialdehyde (MDA). Changes in serum MDA levels during the course of dialysis treatment with a vitamin E-coated regenerated cellulose hollow fiber dialyzer (CL-EE) membrane. At baseline, serum MDA levels were higher in the diabetic (DM; ▪) group than in the non-diabetic (NDM; □) group. After three months of treatment with CL-EE, the MDA concentration significantly decreased in patients of the DM group. However, the NDM patients did not show any significant reduction even after six months. After reverting to CL-PS, serum MDA increased to original levels in the DM group. Data are mean ± SD. #P < 0.01 vs. NDM group; *P < 0.01 vs. baseline level. Kidney International 2001 59, 1943-1950DOI: (10.1046/j.1523-1755.2001.0590051943.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Serum levels of advanced glycation end products (AGEs). Changes in serum AGE levels during the course of dialysis treatment with CL-EE membrane are shown. Serum AGE levels were significantly higher in the DM group (▪) than in the NDM group (□) at all observation points. After one month of treatment with CL-EE, a significant reduction in the AGE concentration was noted in both groups. After three months of CL-EE use, there was a greater decrease in AGE in the DM group than the NDM group. After reverting to CL-PS, serum AGEs in the NDM group returned to baseline levels. Data are mean ± SD. #P < 0.01 vs. NDM group; *P < 0.05 and **P < 0.01, respectively, vs. baseline levels. Kidney International 2001 59, 1943-1950DOI: (10.1046/j.1523-1755.2001.0590051943.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Serum levels of 8-hydroxy-deoxyguanosine (8-OHdG). Changes in serum 8-OHdG levels during the course of dialysis treatment with CL-EE membrane are shown. A significant reduction was noted in the DM group (▪) by three months of treatment with CL-EE. Serum 8-OHdG levels also significantly decreased in the NDM group (□) after six months of treatment. After reverting to CL-PS membrane, serum 8-OHdG tended to increase in both groups. Data are mean ± SD. *P < 0.05 vs. baseline levels. Kidney International 2001 59, 1943-1950DOI: (10.1046/j.1523-1755.2001.0590051943.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Effects of CL-EE on HD-related complications. Schematic diagram of the potential beneficial effects of CL-EE on HD-related complications. Kidney International 2001 59, 1943-1950DOI: (10.1046/j.1523-1755.2001.0590051943.x) Copyright © 2001 International Society of Nephrology Terms and Conditions